(S)-2-((s)-2-氨基-3-甲基丁酰胺)丙酸 | 27493-61-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 天然氨基酸及其衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-2-((s)-2-氨基-3-甲基丁酰胺)丙酸
• 中文别名: 缬氨酰-丙氨酸
• 英文名称: Val-Ala
• 英文别名: HO-Ala-Val-H；H-Val-Ala-OH；L-valyl-L-alanine；Val-Ala-OH；valylalanine；(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]propanoic acid
• CAS: 27493-61-4
• 化学式: C₈H₁₆N₂O₃
• 分子量: 188.227
• InChiKey: HSRXSKHRSXRCFC-WDSKDSINSA-N

物化性质

• 熔点：
  234 °C(Solv: ethanol (64-17-5))
• 沸点：
  401.8±30.0 °C(Predicted)
• 密度：
  1.157 g/cm3(Temp: 26 °C)
• 溶解度：
  溶于二甲基亚砜
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -3.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  96.9
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36
• 海关编码：
  2924199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  -15°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-Val-Ala-OH
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-Val-Ala-OH
CAS number: 27493-61-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H16N2O3
Molecular weight: 188.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

H-Val-Ala-OH（缬氨酸）是由L-缬氨酸和L-丙氨酸残基形成的二肽，具有代谢作用。

靶点

Human Endogenous Metabolite（人类内源性代谢物）

反应信息

• 作为反应物：
  描述：

  (S)-2-((s)-2-氨基-3-甲基丁酰胺)丙酸 在 2-乙氧基-1-乙氧碳酰基-1,2-二氢喹啉 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 51.25h， 生成 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-((4-((S)-7-methoxy-8-(3-(((S)-7-methoxy-2-methyl-5-oxo-5,11a-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)propoxy)-5-oxo-5,11a-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)hexanamide
  参考文献：
  名称：

  [EN] PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES
  [FR] PYRROLOBENZODIAZÉPINES UTILISÉES POUR TRAITER DES MALADIES PROLIFÉRATIVES

  摘要：

  吡咯苯并二氮杂环二聚体I在一个单体单元上具有C2-C3双键和C2位置上的芳基基团，在另一个单体单元上具有C2-C3双键和C2位置上的共轭双键或三键或C2位置上的烷基基团，以及这些化合物的共轭物。

  公开号：

  WO2011130616A1
• 作为产物：
  描述：

  苄氧羰基-L-缬氨酰-L-丙氨酸 在 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以1.2%的产率得到(S)-2-((s)-2-氨基-3-甲基丁酰胺)丙酸
  参考文献：
  名称：

  WO2020006018A5

  摘要：

  公开号：

  WO2020006018A5

文献信息

• [EN] CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES<br/>[FR] DÉRIVÉ DE DIMÈRE DE PYRROLOBENZODIAZÉPINE RÉTICULÉ (PBD) ET SES CONJUGUÉS
  申请人：HANGZHOU DAC BIOTECH CO LTD

  公开号：WO2020006722A1

  公开（公告）日：2020-01-09

  A novel cross-linked cytotoxic agents, pyrrolobenzo-diazepine dimer (PBD) derivatives, and their conjugates to a cell-binding molecule, a method for preparation of the conjugates and the therapeutic use of the conjugates.

  一种新型的交联细胞毒剂，吡咯苯并二氮杂环二聚体（PBD）衍生物，以及它们与细胞结合分子的结合物，一种制备这些结合物的方法以及这些结合物的治疗用途。
• [EN] CONJUGATES FOR TREATING DISEASES<br/>[FR] CONJUGUÉS POUR LE TRAITEMENT DE MALADIES
  申请人：ENDOCYTE INC

  公开号：WO2016148674A1

  公开（公告）日：2016-09-22

  The present disclosure relates to pyrrolobenzodiazepine (PBD) prodrugs and conjugates thereof. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making and methods of using the same.

  本公开涉及吡咯苯并二氮杂环（PBD）前药及其结合物。本公开还涉及所述结合物的药物组合物，制备方法和使用方法。
• Coupling-Reagent-Free Synthesis of Dipeptides and Tripeptides Using Amino Acid Ionic Liquids
  作者：Shinya Furukawa、Takahide Fukuyama、Akihiro Matsui、Mai Kuratsu、Ryotaro Nakaya、Takashi Ineyama、Hiroshi Ueda、Ilhyong Ryu

  DOI：10.1002/chem.201501783

  日期：2015.8.17

  method for the synthesis of dipeptides has been developed, which does not require any coupling reagents. This method is based on the reaction of readily available HCl salts of amino acid methyl esters with tetrabutylphosphonium amino acid ionic liquids. The isolation procedure of stepwise treatment with AcOH is easy to carry out. The method was extended to the synthesis of tripeptide, tyrosyl‐glycyl‐glycine

  已经开发了合成二肽的通用方法，该方法不需要任何偶联剂。该方法基于容易获得的氨基酸甲酯的HCl盐与四丁基phosph氨基酸离子液体的反应。用AcOH逐步处理的分离过程很容易进行。该方法还扩展到IMREG-1中也存在的三肽酪氨酰甘氨酰甘氨酸的合成。
• [EN] NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF<br/>[FR] LIEURS AUTO-IMMOLABLES NON LINÉAIRES ET CONJUGUÉS DE CEUX-CI
  申请人：SYNTHON BIOPHARMACEUTICALS BV

  公开号：WO2018069375A1

  公开（公告）日：2018-04-19

  The present invention relates to linker-drug compounds (LDs) and antibody-drug conjugates (ADCs) comprising a non-linear self-immolative linker, which is cleavable or transformable under appropriate conditions and which reduces the hydrophobicity of the antibody-drug conjugate.

  本发明涉及连接子-药物化合物（LDs）和抗体-药物偶联物（ADCs），包括一个非线性自消除连接子，该连接子在适当条件下可被裂解或转化，并减少了抗体-药物偶联物的疏水性。
• [EN] ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING TROP-2<br/>[FR] ANTICORPS-CONJUGUÉS POUR LE CIBLAGE DE TUMEURS EXPRIMANT TROP -2
  申请人：SYNAFFIX BV

  公开号：WO2020094670A1

  公开（公告）日：2020-05-14

  The present invention concerns antibody-conjugate having general structure (2): AB–[(L 6 )–Z–(L 1) n –(L 2 ) o –(L 3 ) p –(L 4 ) q –D} xx ] yy (2) wherein AB is an antibody capable of targeting Trop-2-expressing tumours and D is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes such as calicheamicins, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, radioisotopes, therapeutic proteins and peptides (or fragments thereof), kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogues or prodrugs thereof. These antibody-conjugates exhibit an improved therapeutic index. The invention further concerns a process for preparing the antibody-conjugate according to the invention, a method for targeting Trop-2-expressing cells, medical uses of the antibody-conjugates according to the invention.

  本发明涉及具有通用结构（2）的抗体偶联物：AB–[(L 6 )–Z–(L 1) n –(L 2 ) o –(L 3 ) p –(L 4 ) q –D} xx ] yy (2) 其中 AB 是一种能够靶向表达 Trop-2 的肿瘤的抗体，D 是从包括紫杉烷类、蒽环类、喜树碱类、epothilones、mytomycins、combretastatins、长春花生物碱、maytansinoids、enediynes（如calicheamicins、duocarmycins、tubulysins、amatoxins、bleomycins、dolastatins 和 auristatins）、吡咯并苯二氮卓二聚体、吲哚并苯二氮卓二聚体、放射性同位素、治疗性蛋白质和肽（或其片段）、激酶抑制剂、MEK 抑制剂、KSP 抑制剂以及它们的类似物或前药中选择的。这些抗体偶联物展现出改进的治疗指数。本发明还涉及根据本发明制备抗体偶联物的过程，一种靶向表达 Trop-2 的细胞的方法，以及根据本发明的抗体偶联物的医疗用途。

表征谱图